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Abstract Drug toxicity frequently goes concealed until clin-
ical trials stage, which is the most challenging, dangerous and
expensive stage of drug development. Both the cultures of
cancer cells in traditional 2D assays and animal studies have
limitations that cannot ever be unraveled by improvements in
drug-testing protocols. A new generation of bioengineered
tumors is now emerging in response to these limitations, with
potential to transform drug screening by providing predictive
models of tumors within their tissue context, for studies of
drug safety and efficacy. Considering the NCI60, a panel of
60 cancer cell lines representative of 9 different cancer types:
leukemia, lung, colorectal, central nervous system (CNS),
melanoma, ovarian, renal, prostate and breast, we propose to
review current Bstate of art^ on the 9 cancer types specifically
addressing the 3D tissue models that have been developed and
used in drug discovery processes as an alternative to comple-
ment their study.
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Introduction
Cancer is a major cause of morbidity and mortality world-
wide, with disease burden estimated to increase in the coming
decades. Nonetheless, we are living through an exciting era
for cancer drug discovery and development, full of enormous
opportunities and challenges. Scientific advances in drug dis-
covering technologies such as genomic methods, drug screen-
ing technologies, tissue engineering and microfluidics lead to
the witnessing of a host of technology changes and new in-
sights into the biology of neoplasia. Despite these advances,
testing of new molecules in the clinical stages of development
remains a lengthy process associated with a high failure rate
[1].
Cancer is a unique term that designates a complex and
diversified disease that calls for at least 100 different types
of cancer and can virtually affect any part of the body [2].
Malignant tumors or neoplasms may also be used to refer to
this condition, whose main feature is the rapid proliferation of
abnormal cells, which can then invade other tissues. This pro-
cess is known as metastasis and it is one of the main causes of
cancer deaths [2].
Cancer therapy is a rather young medical discipline which,
from 1950’s up to now has resulted in the approval of nearly
183 anti-cancer drugs [3, 4]. It also poses an unprecedented
challenge to big pharmaceutical industry since the costs for
the development of a single anti-cancer drug can reach up to
US$ 1 billion [5, 6]. The process of drug development in-
volves critical and systematic steps with many drawbacks
and turnarounds. It is estimated that per 10,000 compounds
analyzed for different applications, only one reaches approval
[6]. In the case of anticancer drugs, the attrition rates are even
higher, since only 5% of substances passing clinical testing are
later licensed and many others commercially available are
later withdrawn from the market [7]. This high attrition rates
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can be mainly attributed to the inexistence of adequate pre-
clinical models to test their efficacy and toxicity [7]. It is
therefore urgent to develop new nanopharmaceuticals release
systems as well as efficient drug screening methodologies that
are able to mimic the behavior in the human body and predict
the future success of specific drugs.
Since 1995, the process of testing a new potential anti-
cancer drug involves an initial pre-screening using 3 cell lines,
MCF-7 breast cancer, NCI-H460 large-cell lung cancer and
SF268 glioblastoma cancer cell lines [5, 8]. Only then, if the
substance inhibits growth of at least one of the cell lines, it
proceeds to be tested using the NCI60, a panel of 60 cancer
cell lines representative of 9 different cancer types: leukaemia,
lung, colorectal, central nervous system (CNS), melanoma,
ovarian, renal, prostate and breast [8, 9]. Up to now, the
NCI60 panel has allowed testing of more than 70,000 com-
pounds, including all chemotherapeutic agents currently used
[10]. Preoccupying evidence is arising on whether commonly
used cancer cell lines are representative of the tumors they
intend to mimic [11].
The most frequently used model for in vitro study of mam-
malian cells is the monolayer of cells. Even though the two-
dimensional (2D) model has indubitable given us a significant
knowledge amount in biological research, it has certain limita-
tions that have encouraged the development of three-
dimensional (3D) models. The complex nature of tumors and
the influence of the surrounding microenvironment which 2D
cell cultures alone, cannot recapitulate. The lack of such com-
plexity may provide inaccurate information regarding the effi-
cacy of such treatments, thus jeopardizing the development of
appropriate chemotherapy drugs (Fig. 1). Additionally, there
are basic differences between 2D and 3D cultures that empha-
size the need to use both screening systems. Themorphology of
cells is affected by its growth medium: in 2D, cancer cells
display an unnatural morphology, while in 3D they adopt a
rounded shape, forming clusters that are suggestive of tumors
in vivo [13, 14]. Growth rates also differ according to their
environment, as cancer cells grow faster in 2D than in 3D
[15]. According to some mathematical models, the latter re-
flects better the in vivo growth rates of cancer cells [16].
Molecular differences (such as differential gene expression pro-
files in key genes involved in angiogenesis, cell migration and
invasion) have also been highlighted between cancer cells
grown in 2D or in 3D [17–19]. Finally, numerous reports have
emphasized important differences in drug responses of cancer
cells grown in 2D compared to 3D [20–22]. Although these
results are highly dependent on the type of cell and drug, an
overall higher resistance to treatments has been observed in 3D
tests, which may provide a possible explanation to drug resis-
tance phenomena observed in some patients. It is the added
dimensionality of 3D cultures that is the critical feature leading
to the differences in cellular responses because not only it in-
fluences the spatial organization of the cell surface receptors
engaged in interactions with surrounding cells, but it also in-
duces physical constraints to cells. Nutrients, growth factors or
drugs may not be able to fully penetrate the 3D system to reach
cells near the core, more resistant to treatment compared to
those in 2D culture system, often being better predictors of
in vivo drug responses. Also, as cytostatic drugs mainly target
proliferating cells, cancer cell dormancy is considered as a ma-
jor resistance mechanism to this class of anti-cancer drugs, only
reproduced by 3D models dormant tumor regions [23].
In this paper we review current Bstate of art^ on the 9
cancer types represented by the NCI60 cell line panel, specif-
ically addressing the 3D tissue engineering models have been
developed and used in drug discovery processes as an alter-
native to complement their study. The potential of using 3D
cell models for anti-cancer drug screening is here critically
assessed, and its main advantages and limitations dissected.
Furthermore, we also compile current information regarding
anti-cancer drug testing in 3D versus 2D and critically assess
their potential impact in the discovery processes of novel che-
motherapy drugs.
Tissue Engineering
Tissue engineering aims at providing biological substitutes to
restore or replace tissue and organ function, as an alternative
to currently available conventional options, such as transplan-
tation, surgical reconstruction, artificial prosthesis or supple-
mentation of the metabolic products [24].
3D culture systems can be subdivided as scaffold-free or
scaffold-based (of natural or synthetic origin) methods [25,
26]. One of the most commonly used scaffold-free 3D cancer
models are multicellular tumor spheroids, which are formed
due to the ability of cells in suspension to self-assemble in the
absence of an attachment surface or scaffold [27]. These are
simple and easy to produce and can be constituted of one or
more cell types. Their small size and the absence of vascular-
ization create limitations to nutrients and oxygen diffusion,
requiring cells of its core to adopt a glycolytic metabolic ac-
tivity which causes an increasing pH gradient towards the
outside (Fig. 2) [28]. This mimics what happens with tumors
in vivo, which display regions of hypoxia and of acidity ac-
cording to the distance to tumor blood vessels, as can be seen
in Fig. 2 [28–30]. Spheroids can be fabricated using several
methods: hanging drop method, in which cells can aggregate
freely at the bottom of an inverted cell suspension drop; spin-
ner flasks method, which provides constant agitation,
allowing spontaneous cell aggregation; static liquid overlay
technique, which enables spheroid formation by preventing
cell adhesion to the growth substrate; centrifugation; and
growing cells on non-adherent micropatterned surfaces in
microfabricated devices to favor their aggregation [31].
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Other studies use scaffold-based methods for building 3D
tumor models, either of synthetic or natural origin [26, 28].
There are still manifest limitations associated to any of these
strategies to build 3D cancer models, which need to be opti-
mized to better mimic the complex tumor characteristics and
its interactions with the surrounding stroma, and ultimately be
incorporated in routine tests for testing anti-cancer drugs.
Another promising technology arising in drug discovery for
cancer research is microfluidics. Microfluidics allow the fab-
rication of 3D architectures with controlled spatial relations
between cells inside a chip, the presence of flow-induced sig-
naling and transduction, and the capacity to introduce the
chemical gradients necessary to reproduce the architecture of
the in vivomicroenvironment [32]. This technology, generally
combined with Tissue Engineering, has provided instrumental
data and previously unmeasurable or unobservable informa-
tions about cancer-related processes, such as angiogenesis and
metastasis, and have proved instrumental in drug discovery
[26].
3D Tissue Engineered Cancer Models in Drug
Discovery
The most recent reports on 3D models applied in anti-cancer
drug discovery is succinctly depicted in Table 1 and will be
further discussed herein.
Melanoma
Of all types of skin cancer, melanoma is the most malignant
form that presents the highest mortality rates within Europe
and United States of America, which is increasing dramatical-
ly at a rate of 3–7% a year [60, 61].While the surgical removal
of these early neoplastic cells results in 90% of cure rates, its
late detection has a poor survival prognosis [62], mainly be-
cause metastatic disease derived from melanoma fails to re-
spond to most treatments Despite the success of conventional
drugs to inhibit cell growth in 2D cultures, most of them fail to
do so in 3D tissue cultures, suggesting a potential role of the
cellular microenvironment in the process of melanoma devel-
opment. Indeed, the complexity of skin tissues and its cell
interactions are hardly matched by 2D cultures.
Another crucial feature of melanomas is their ability to
stimulate the formation of capillaries to supply the tumor
and to penetrate the vessel walls to initiate metastatic process
[63, 64]. This emphasizes the need for models with different
cell types, especially, vascularized, in order to allow the eval-
uation of drugs that interfere in this processes, as they may be
a key target to fight it [65]. The use of animal skin models to
study melanoma progression is also not an alternative, since
substantial differences exist between human and animal skin.
For instance, murine dermis is thin and comprises typically 3
layers of epidermis, while human possesses a thick dermis and
between 6 and 10 layers of epidermis. For all these reasons,
Fig. 1 Schematic representation
of the potential role of 3D TE
models in cancer research,
namely in drug development as a
complement to 2D cell culture
and animal models. The
correlation here represented refers
to the Pearson Correlation
Coefficient comparing gene
expression in spontaneous SCC
tumors with 3D organotypic
models, mouse and 2D models.
Adapted from Ridky et al. [12]
Fig. 2 Schematic representation of a spheroid model. Hypoxic nucleus
containing necrotic cells, surrounded by quiescent cells and by an outer
layer of actively proliferating cells
Stem Cell Rev and Rep
T
ab
le
1
E
xa
m
pl
es
of
dr
ug
s
sc
re
en
ed
us
in
g
3D
T
is
su
e
en
gi
ne
er
ed
m
od
el
s
in
N
C
I6
0
9
di
ff
er
en
tc
an
ce
r
ty
pe
s
C
an
ce
r
ty
pe
M
od
el
s
D
ru
g
O
ut
co
m
es
R
ef
er
en
ce
M
el
an
om
a
H
ig
h-
th
ro
ug
hp
ut
3D
sp
he
ro
id
5-
fl
uo
ro
ur
ac
il;
T
ir
ap
az
am
in
e
5-
fl
uo
ro
ur
ac
il
(5
-F
U
)
ha
s
hi
gh
er
an
ti-
pr
ol
if
er
at
iv
e
ef
fe
ct
s
on
2D
cu
ltu
re
s
w
he
re
as
th
e
hy
po
xi
a
ac
tiv
at
ed
dr
ug
co
m
m
on
ly
re
fe
rr
ed
to
as
tir
ap
az
am
in
e
(T
PZ
)
ar
e
m
or
e
ef
fe
ct
iv
e
ag
ai
ns
t
3D
cu
ltu
re
s
[3
3]
3D
H
A
hy
dr
og
el
s
B
R
A
F
in
hi
bi
to
rs
(D
ab
ra
fe
ni
b)
;E
R
K
in
hi
bi
to
rs
(V
X
-1
1E
);
C
is
pl
at
in
3D
–e
xt
ra
ce
lu
la
r
m
at
ri
x
(E
C
M
)
hy
br
id
hy
dr
og
el
s
ar
e
la
rg
el
y
in
se
ns
iti
ve
to
da
br
af
en
ib
.V
X
11
ha
s
a
m
uc
h
st
ro
ng
er
ef
fe
ct
[3
4]
sk
in
eq
ui
va
le
nt
,m
ad
e
of
pr
im
ar
y
fi
br
ob
la
st
s
em
be
dd
ed
in
to
a
co
lla
ge
n
I
sc
af
fo
ld
an
d
co
ve
re
d
w
ith
ke
ra
tin
oc
yt
es
,w
ith
m
et
as
ta
tic
m
el
an
om
a
ce
ll
sp
he
ro
id
s
T
R
A
IL
+
U
V
B
an
d
T
R
A
IL
+
ci
sp
la
tin
E
xt
en
si
ve
ce
ll
de
at
h
in
2D
cu
ltu
re
.M
el
an
om
a
sp
he
ro
id
s
ar
e
po
te
nt
ly
ki
lle
d
by
T
R
A
IL
+
ci
sp
la
tin
tr
ea
tm
en
tb
ut
bu
tn
ot
by
th
e
T
R
A
IL
+
U
V
B
co
m
bi
na
tio
n.
[3
5]
O
va
ri
an
C
an
ce
r
Sp
he
ro
id
s
em
be
dd
ed
in
3D
P
E
G
-h
yd
ro
ge
l
P
ac
lit
ax
el
H
ig
he
r
su
rv
iv
al
ra
te
s
af
te
r
ex
po
su
re
to
th
e
an
ti-
ca
nc
er
dr
ug
pa
cl
ita
xe
lw
er
e
ob
se
rv
ed
in
ce
ll
sp
he
ro
id
s
gr
ow
n
in
hy
dr
og
el
s
(4
0–
60
%
)
co
m
pa
re
d
to
ce
ll
m
on
ol
ay
er
s
in
2D
(2
0%
)
[3
6]
Sp
he
ro
id
s
em
be
dd
ed
in
3D
P
E
G
-h
yd
ro
ge
l
P
ac
lit
ax
el
an
d
K
L
K
/M
A
PK
in
hi
bi
to
rs
T
he
re
sp
on
se
to
pa
cl
ita
xe
lw
as
im
pr
ov
ed
by
co
m
bi
na
to
ri
al
pa
cl
ita
xe
lt
re
at
m
en
tw
ith
K
L
K
/in
te
gr
in
/M
A
PK
in
hi
bi
tio
n.
[3
7]
3D
ca
nc
er
sp
he
ro
id
s
in
38
4
w
el
lh
an
gi
ng
dr
op
ar
ra
y
pl
at
fo
rm
C
is
pl
at
in
D
tu
m
or
sp
he
ro
id
s
de
m
on
st
ra
te
d
gr
ea
te
r
re
si
st
an
ce
(7
0–
80
%
vi
ab
ili
ty
)t
o
ci
sp
la
tin
ch
em
ot
he
ra
py
co
m
pa
re
d
to
2D
cu
ltu
re
s
(3
0–
50
%
vi
ab
ili
ty
).
[3
8]
R
en
al
ca
nc
er
3D
sc
af
fo
ld
ut
ili
zi
ng
M
at
ri
ge
la
nd
ra
tt
ai
l
co
lla
ge
n
I
C
is
pl
at
in
,G
en
ta
m
ic
in
,a
nd
D
ox
or
ub
ic
in
3D
tis
su
e
m
od
el
ha
d
a
di
ff
er
en
tt
im
in
g
of
to
xi
ci
ty
in
du
ct
io
n
co
m
pa
re
d
to
2D
cu
ltu
re
an
d
w
as
m
or
e
se
ns
iti
ve
to
dr
ug
do
sa
ge
w
ith
lo
w
er
L
D
50
va
lu
es
[3
9]
B
re
as
t
3D
co
lla
ge
n
ba
se
d
sc
af
fo
ld
Ta
m
ox
if
en
Ta
m
ox
if
en
re
du
ce
d
re
si
du
al
ep
ith
el
ia
lv
ol
um
e
in
(E
R
+
)t
um
or
s
bu
tn
ot
in
E
R
lo
w
/−
tu
m
or
s
[4
0]
3D
ch
ito
sa
n
sc
af
fo
ld
Ta
m
ox
if
en
ta
m
ox
if
en
in
du
ce
d
50
%
re
du
ct
io
n
in
ce
ll
gr
ow
th
in
2d
an
d
15
%
re
du
ct
io
n
in
ce
ll
gr
ow
th
in
ch
ito
sa
n
sc
af
fo
ld
[4
1]
Sp
he
ro
id
s
U
01
26
,P
K
C
41
2,
PF
23
41
06
6,
da
sa
tin
ib
,
an
d
ax
iti
ni
b,
is
on
aa
m
id
in
e
B
,p
ap
ua
m
in
e,
m
yc
al
ol
id
e
E
,a
nd
ja
sp
am
id
e.
re
si
st
an
ce
to
th
e
cy
to
to
xi
c
ag
en
td
ox
or
ub
ic
in
in
3D
cu
ltu
re
s
[4
2]
Sp
he
ro
id
s
ni
cl
os
am
id
e
N
ic
lo
sa
m
id
e
w
as
id
en
tif
ie
d
fr
om
th
e
L
O
PA
C
ch
em
ic
al
lib
ra
ry
of
12
58
co
m
po
un
ds
.D
ow
nr
eg
ul
at
ed
st
em
pa
th
w
ay
s,
in
hi
bi
te
d
th
e
fo
rm
at
io
n
of
sp
he
ro
id
s,
an
d
in
du
ce
d
ap
op
to
si
s
in
br
ea
st
ca
nc
er
.
[4
3]
S p
he
ro
id
s
in
3D
la
m
in
in
-r
ic
h
M
at
ri
ge
l
D
ox
or
ub
ic
in
,U
01
26
,C
I-
10
40
,P
D
18
43
52
(M
E
K
in
hi
bi
to
rs
),
w
or
tm
an
ni
n
H
ig
he
r
re
si
st
an
ce
to
do
xo
ru
bi
ci
n
in
3D
cu
ltu
re
s.
M
E
K
in
hi
bi
to
rs
pr
od
uc
ed
a
si
m
ila
r
in
hi
bi
tio
n
in
2
an
d
3D
.
in
hi
bi
tio
n
of
ph
os
ph
at
id
yl
in
os
ito
l3
′-k
in
as
e
ac
tiv
ity
by
w
or
tm
an
ni
n
ha
d
no
si
gn
if
ic
an
te
ff
ec
to
n
th
e
gr
ow
th
of
an
y
of
th
e
ce
lls
in
ei
th
er
2D
or
3D
[4
4]
3D
liv
er
ce
lls
en
ca
ps
ul
at
ed
hy
dr
og
el
s
co
-c
ul
tu
re
d
w
ith
br
ea
st
ca
nc
er
ce
lls
ac
et
am
in
op
he
n,
di
cl
of
en
ac
,r
if
am
pi
n
an
d
qu
in
id
in
e
C
T
5
0
va
lu
e
of
fo
ur
dr
ug
s
de
ri
ve
d
fr
om
th
e
do
se
-d
ep
en
de
nt
te
st
in
g
co
rr
el
at
e
w
el
lw
ith
th
e
re
po
rt
ed
in
vi
vo
L
D
5
0
va
lu
es
.
[4
5]
L
eu
ka
em
ia
3D
fi
br
in
og
en
sc
af
fo
ld
de
ri
ve
d
fr
om
th
e
B
on
e
M
ar
ro
w
su
pe
rn
at
an
to
f
M
ul
tip
le
M
ye
lo
m
a
pa
tie
nt
s
bo
rt
ez
om
ib
an
d
ca
rf
ilz
om
ib
H
ig
he
r
re
si
st
an
ce
of
M
M
ce
lls
to
th
er
ap
y
w
as
ob
se
rv
ed
w
he
n
M
M
ce
lls
w
er
e
m
ul
ti-
cu
ltu
re
d
w
ith
ac
ce
ss
or
y
ce
lls
in
th
e
3D
(r
ep
re
se
nt
in
g
th
e
ro
le
of
bo
ne
m
ar
ro
w
m
ic
ro
en
vi
ro
nm
en
t
an
d
cy
to
ki
ne
s.
H
yp
ox
ia
an
d
dr
ug
gr
ad
ie
nt
co
nt
ri
bu
te
d
to
th
e
dr
ug
re
si
st
an
ce
to
bo
rt
ez
om
ib
an
d
ca
rf
ilz
om
ib
[4
6]
Stem Cell Rev and Rep
T
ab
le
1
(c
on
tin
ue
d)
C
an
ce
r
ty
pe
M
od
el
s
D
ru
g
O
ut
co
m
es
R
ef
er
en
ce
C
ol
or
ec
ta
l
Sc
af
fo
ld
ba
se
d
(3
D
th
in
ge
lo
f
M
at
ri
ge
l)
an
d
sp
he
ro
id
s
E
G
FR
ty
ro
si
ne
ki
na
se
in
hi
bi
to
r
A
G
14
78
Si
gn
if
ic
an
tm
or
ph
ol
og
ic
di
ff
er
en
ce
s;
ch
an
ge
s
in
ge
ne
ex
pr
es
si
on
pa
tte
rn
s
th
at
w
as
in
lin
e
w
ith
th
e
se
ns
iti
vi
ty
to
an
ti-
E
G
F
R
ta
rg
et
ed
th
er
ap
y
[4
7]
sp
he
ro
id
s
ci
sp
la
tin
,m
el
ph
al
an
an
d
vi
nb
la
st
in
e,
N
SC
64
78
89
N
ov
el
dr
ug
s
th
at
sh
ow
co
ns
id
er
ab
ly
st
ro
ng
er
cy
to
to
xi
c
ac
tiv
ity
in
3-
D
cu
ltu
re
co
m
pa
re
d
to
st
an
da
rd
ag
en
ts
ca
n
be
id
en
tif
ie
d
[4
8]
B
io
re
ac
to
r
an
d
3D
co
lla
ge
n
sc
af
fo
ld
5-
Fl
uo
ro
ur
ac
il,
A
B
T-
19
9
(B
C
L
-2
in
hi
bi
to
r)
B
C
L
-2
in
hi
bi
to
rA
B
T-
19
9
in
du
ce
d
cy
to
to
xi
c
ef
fe
ct
s
in
p3
D
bu
t
no
ti
n
2D
cu
ltu
re
s
[4
9]
E
x
vi
vo
co
lo
sp
he
re
s
5-
fl
uo
ro
ur
ac
il
an
d
ir
in
ot
ec
an
C
ol
os
ph
er
es
m
at
ch
ed
th
e
ge
ne
ex
pr
es
si
on
pr
of
ile
of
th
e
pa
re
nt
xe
no
gr
af
tt
is
su
e
an
d
re
pr
od
uc
ed
th
e
sa
m
e
re
sp
on
se
s
fo
r
5-
fl
uo
ro
ur
ac
il
an
d
ir
in
ot
ec
an
[5
0]
T
um
or
sp
he
ro
id
s
in
a
m
ic
ro
w
el
l-
ba
se
d
m
ic
ro
fl
ui
di
c
ch
ip
D
ox
or
ub
ic
in
an
d
Pa
cl
ita
xe
l
M
T
S
ex
hi
bi
te
d
m
or
e
re
si
st
an
ce
to
th
e
dr
ug
s
th
an
th
os
e
of
2D
cu
ltu
re
[5
1]
M
ul
tic
el
lu
la
r
sp
he
ro
id
s
in
co
lla
ge
n
I
ge
ls
LY
29
40
02
(P
I3
K
in
hi
bi
to
r)
Fi
br
ob
la
st
s
w
er
e
no
ta
ff
ec
te
d
by
th
e
dr
ug
;h
ig
he
r
ap
op
to
si
s
in
du
ce
d
by
th
e
dr
ug
in
th
e
sp
he
ro
id
s
w
he
n
co
m
pa
re
d
to
co
nt
ro
l.
[5
2]
el
ec
tr
os
pu
n
po
ly
(ε
-c
ap
ro
la
ct
on
e)
(P
C
L
)
na
no
fi
br
ou
s
sc
af
fo
ld
(N
FS
).
m
ito
xa
nt
ro
ne
M
im
ic
ke
d
th
e
cr
os
s-
ta
lk
be
tw
ee
n
B
M
-D
C
s
an
d
m
ito
xa
nt
ro
ne
-t
re
at
ed
C
T
26
ca
nc
er
ce
lls
[5
3]
C
N
S
Sp
he
ro
id
C
ar
ve
di
lo
la
nd
im
at
in
ib
C
om
bi
na
tio
n
tr
ea
tm
en
to
f
im
an
iti
b
m
es
yl
at
e
an
d
ca
rv
ed
ilo
l
re
su
lts
in
sy
ne
rg
is
tic
in
hi
bi
tio
n
of
C
6
gl
io
m
a
ce
ll
gr
ow
th
.
T
he
m
os
te
ff
ec
tiv
e
re
du
ct
io
n
of
sp
he
ro
id
vo
lu
m
e
w
as
ob
se
rv
ed
in
th
e
C
A
R
-t
re
at
ed
gr
ou
p
[5
4]
Sp
he
ro
id
Pa
cl
ita
xe
l
L
ip
os
om
e
co
nj
ug
at
ed
w
ith
R
G
D
an
d
T
F
s
to
lo
ad
ed
w
ith
pa
cl
ita
xe
lp
re
se
nt
ed
th
e
be
st
an
tip
ro
lif
er
at
iv
e
ac
tiv
ity
ag
ai
ns
t
C
6
ce
lls
an
d
tu
m
or
sp
he
ro
id
s.
[5
5]
L
un
g
M
ic
ro
fl
ui
di
c
ch
ip
-b
as
ed
,(
3D
)
co
-c
ul
tu
re
dr
ug
se
ns
iti
vi
ty
te
st
pl
at
fo
rm
G
ef
iti
ni
b,
pa
cl
ita
xe
la
nd
ge
m
ci
ta
bi
ne
G
ef
iti
ni
b
w
as
th
e
m
os
te
ff
ic
ac
io
us
dr
ug
in
3D
,d
ru
g
se
ns
iti
vi
ty
te
st
in
g
in
pr
im
ar
y
ca
nc
er
ce
lls
di
ff
er
s
si
gn
if
ic
an
tly
fr
om
th
at
in
ca
nc
er
ce
ll
lin
es
[5
6]
D
ec
el
lu
la
ri
ze
d
tis
su
e
m
at
ri
x
G
ef
iti
ni
b
N
o
si
gn
if
ic
an
te
ff
ec
tw
as
ob
se
rv
ed
in
co
nv
en
tio
na
lc
el
lc
ul
tu
re
.
L
ow
er
pr
ol
if
er
at
io
n
ra
te
co
m
pa
re
d
to
2D
ce
ll
cu
ltu
re
[5
7]
P
ro
st
at
e
3D
m
ic
ro
ag
gr
eg
at
es
D
oc
et
ax
el
ce
lls
cu
ltu
re
d
in
3D
w
er
e
m
or
e
re
si
st
an
tt
o
al
ld
os
es
of
do
ce
ta
xe
lw
he
n
co
m
pa
re
d
to
2D
[5
8]
3D
co
lla
ge
n
ge
ls
ph
er
oi
ds
N
C
I
D
iv
er
si
ty
C
om
po
un
d
L
ib
ra
ry
T
hi
s
sy
st
em
id
en
tif
ie
d
ni
ne
co
m
po
un
ds
ex
hi
bi
tin
g
hi
gh
po
te
nc
y
an
d
lo
w
to
xi
ci
ty
w
er
e
id
en
tif
ie
d,
in
cl
ud
in
g
D
X
-5
2-
1
[5
9]
H
ya
lu
ro
ni
c
ac
id
-b
as
ed
hy
dr
og
el
fo
r
ca
nc
er
ce
ll
en
ca
ps
ul
at
io
n
C
am
pt
ot
he
ci
n,
do
ce
ta
xe
la
nd
ra
pa
m
yc
in
C
am
pt
ot
he
ci
n
di
sp
la
ye
d
hi
gh
er
in
du
ct
io
n
of
ap
op
to
si
s
in
3D
,
w
hi
le
fo
rt
he
re
m
ai
ni
ng
tr
ea
tm
en
ts
no
si
gn
if
ic
an
td
if
fe
re
nc
es
w
er
e
ob
se
rv
ed
.
[1
4]
Stem Cell Rev and Rep
the use of 3D human skin models in the context of melanoma
study is extremely relevant.
The need to complement 2D tests with 3D studies is well
demonstrated in the case of melanoma, since A431.H9 human
epithelial carcinoma cell spheroids displayed different re-
sponses to anticancer drugs, compared to 2D cultures [33].
When organized in spheroids, these cells were less sensitive
to the anti-proliferative effects of the anti-cancer drug 5-
fluorouracil (5-FU). The hypoxia activated citotoxin,
tirapazamine (TPZ), had the opposite effect, with cells
displaying less resistance when grown as spheroids than in
2D monolayers [33]. These imparities are strong indicators
of physiological differences associated with culture environ-
ment and the higher efficacy of TZP against cells in 3D envi-
ronment might therefore be related to hypoxic core and limit-
ed oxygen diffusion characteristic of spheroids. 5-FU targets
mostly cells that are actively dividing, thereby explaining the
minor sensitivity of cells in spheroids. Additionally, the propor-
tion of necrotic/proliferating cells may also explain why more
sharpened differences were observed for bigger spheroids in
comparison to 2D cell cultures [66]. This model advantage is
the controlled size spheroids it produces, being limited by the
diameter of the plateau on the bottom surface.
Another testing system, developed by Vorsmann and col-
leagues [35], has incorporated a skin equivalent, made of pri-
mary fibroblasts embedded into a collagen I scaffold and cov-
ered with keratinocytes, with metastatic melanoma cell spher-
oids (451-LU). This system allowed testing the effects of the
Tumor Necrosis Factor-related Apoptosis Inducing Ligand
(TRAIL), a recently developed method for inducing malig-
nant cell apoptosis that involves the administration of com-
pounds belonging to the Tumor Necrosis Factor (TNF) super-
family. Tests performed using this system have revealed sig-
nificant differences in responses to treatments in comparison
to 2D cultures. The combination of TRAIL with sub-lethal
doses of either ultraviolet-B radiation (UVB) or cisplatin
displayed similar efficacy at inducing cancer-cell death in
2D cultures. However, when they were tested using this
skin-equivalent, no effect was observed in the co-treatment
with TRAIL and UVB, but a potent effect was observed when
treated with the TRAIL-cisplatin combination [35].
Blehm et al. [34] have tackled an essential issue in mela-
noma cancer: the problem of brain metastases. The team con-
structed platforms recreating the brain extracellular matrix
(ECM) composition, mimicking the brain^s perivascular
niche and hyaluronic acid (HA) rich parenchyma. The tumor
growth in an HA-rich 3D matrix seeded with Fibronectin and
Laminin was studied to determine the effect of cell microen-
vironment interactions on cell proliferation. Results revealed
that ERK inhibitors (VX-11) has a much stronger effect on
tumor clusters, generally affecting each cluster by inducing
cell death throughout the cluster. Dabrafenib appears to be less
potent, with entire clusters remaining unaffected and cell
death only occurring in isolated cells at the cluster periphery.
These data suggest the complexity inherent to determining
drug efficacy in distinct microenvironments, and therefore
the relevance of such models in drug discovery.
Such significant therapeutic differences in 3D models of
human skin-melanoma, in comparison with 2D models, high-
light the need to more complex representation of in vivo sce-
narios, in order to allow a better understanding of the biolog-
ical processes underlying tumor aggressiveness, invasiveness
potential and resistance to treatments.
Another emergent field in cancer research is immune on-
cology. This emerging field of cancer research can take ad-
vantage of three-dimensional culture technologies, which em-
phasizes the tumor architecture and therefore affects cancer
cell–immune system interaction by regulating differentiation
patterns of myeloid cells but mainly by decreasing the sensi-
tivity of tumor cells to lymphocyte effector functions. An ex-
ample was explored by Ramgolam et al., who formed mela-
noma spheroids neural crest cell medium confirmed that
spheroids display enhanced migratory/invasive capacities
[67]. In immune activation assays, spheroid cells elicited a
poorer allogeneic response from immune cells and inhibited
mitogen-dependent T cells activation and proliferation more
efficiently than their adherent counterparts. Our findings re-
veal a novel immune-modulator function of melanoma spher-
oids and suggest specific roles for spheroids in invasion and in
evasion of antitumor immunity [67].
Ovarian Cancer
Ovarian cancer is the eighth most common type of cancer in
women [68] , of which the most frequent and lethal form is the
ovarian epithelial carcinoma (OEC), responsible for mortality
rates around 55% Treatments for this disease typically involve
surgery for removing the tumor, followed by a platinum-based
chemotherapy (cisplatin or carboplatin) in combination with
taxane (paclitaxel or docetaxel), which will target cell prolif-
eration processes and inhibit cancer progression [69, 70]
However, similar to other cancer types, drug efficacy results
may vary significantly when cells are grown in 2D or in 3D.
Ovarian tumors are complex mixtures of carcinogenic, fibro-
blasts, mesothelial and inflammatory cells, hard to mimic in
2D cultures [71].
Despite this, the number of studies addressing this problem
is fairly limited [72] and most of them use ovarian cancer cell
spheroids grown in different matrices to assess chemotherapy.
The discovery of new ovarian anti-cancer drugs would
benefit from the existence of 3D pre-clinical models of tumor
invasion, as a typical feature of this kind of tumors is the
formation of malignant spheroids that invade the peritoneal
cavity at later stages of the disease [73]. This has been
attempted by Loessner et al. [36], who grew ovarian cell lines
(OV-MZ-6 and SKOV-3) derived from peritoneal ascites of
Stem Cell Rev and Rep
EOC onto synthetic polyethylene glycol-based hydrogel ma-
trixes, modified to contain cell integrin-binding motifs and to
be degraded by cell secreted metalloproteases [36] (Fig. 3). In
this 3D environment, cells were able to proliferate and to
aggregate into spheroids, which displayed higher survival
rates after exposure to paclitaxel (40–60%) than cells grown
in 2D (20%). Furthermore, this model has later allowed to
understand the role of a particular set of proteins (kallikrein-
related peptidases 4–7) in tumor invasion and revealed, for
instance, that a combination of paclitaxel along with inhibition
of those proteins would be more efficient in preventing me-
tastasis [37]. Moreover, the spheroids presented sizes between
5 and 20 μm3 × 104, mimicking the difficulty of the drug to
diffuse through the cell aggregation.
Spheroids are still the easiest way to perform tests in
3D, however, they require high starting cell numbers,
and are of hard long-term maintenance. Raghavan
et al. [38] generate stable, uniform multicellular spher-
oids using a very small number of ovarian cancer cells
in a novel 384-well hanging drop array platform, making it
very expedite to test anti-cancer drugs. Spheroids presented
sizes between 42.60 and 475.22 × 103 μm2 for A2780 cells
and 37.24281.01 × 103 μm2 for OVCAR3 cells. As expected,
when compared to 2D controls, 3D tumor spheroids demon-
strated greater resistance (70–80% viability) to cisplatin
chemotherapy.
Another attempt to mimic the invasion into the peritoneal
cavity has been achieved by culturing primary human fibro-
blasts in a collagen I ECM, covered with a primary human
mesothelial cell layer [71]. On top, a thin layer of collagen I
was placed and covered with ovarian cancer cells, displaying
histological characteristics similar to those of real patients’
metastasis samples [71]. These cancer cell lines, when grown
in direct contact with mesothelial cells, have their adhesion
and proliferation inhibited. On the contrary, their direct con-
tact with fibroblasts renders them more adhesive and invasive
[71]. This model highlights the more relevant role of cell in-
teraction rather than ECM in the determination of ovarian
cancer invasion behavior.
Nevertheless, these complex 3D models show promising
potential to contribute for a better understanding of ovarian
cancer development and contribute to the discovery of new
treatments.
Renal Cancer
Renal cancer is formed in kidney tissues and includes several
types of carcinomas, with renal-cell carcinoma being the most
frequent, responsible for about 85% of the cases [74] and
corresponding to about 2% of all new cancer cases diagnosed
globally [75]. Development of more efficient therapies is
therefore fundamental to increase success rates, because after
Fig. 3 3D spheroid models for
drug testing in cancer research. A)
Melanoma spheroids respond to
combination treatment in vitro.
20 h later, spheroids were stained
for apoptosis using FITC-labeled
AnnexinV (green) and propidium
iodide (PI, red) and analyzed by
immunofluorescence microscopy.
Reprinted with permission from
[35]. Copyright, 2013 Nature
Publishing Group. b) Epithelial
ovarian cancer cells (EOC) in 2D
and 3D embedded within
hydrogels grew as spheroids
imaged by phase contrast (top
panel) and confocal (bottom
panel, maximal projection)
microscopy. Reprinted with
permission from [36]. Copyright,
2015 Elsevier
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the appearance of metastasis the effective response to cytotox-
ic, hormonal and radio therapies is below 10% [76–78].
Regardless the evident advantages of testing promising
therapeutic drugs using in vitro 3Dmodels, few attempts have
been made to reconstruct kidney, most of them consisting in
growing cells onto scaffolds, made of collagen I, Matrigel,
thermo responsive polymers, hollow fibers or pre-molded bio-
degradable polymers [79, 80]. Perhaps this is a result of the
difficulty to mimic kidney’s complex structure by in vitro
models, as scaffolds hardly mimic the biochemical, spatial
and vascular characteristics of the native kidney ECM [80,
81]. Kidneys physiological role in the organism (blood filtra-
tion, electrolyte, acid-base and blood pressure balance, among
others) makes it an organ particularly sensitive to drug toxicity
[39]. The anticancer drug cisplatin is a good example of this
scenario, for despite its chemotherapeutic efficiency against
several solid cancers, it is known to cause renal dysfunction in
patients receiving high doses [82]. To study renal toxicity,
DesRochers et al., [39] have bioengineered a 3D kidney tissue
model using immortalized human renal cortical epithelial cells
in a 3D Matrigel scaffold and rat tail collagen I with kidney
functions similar to that found in vivo. These 3D tissues were
compared to 2D cell cultures in terms of both acute (3 days)
and chronic (2 weeks) toxicity induced by Cisplatin,
Gentamicin, and Doxorubicin. Result show that 3D tissues
were more sensitive to drug-induced toxicity and, unlike the
2D cells, were capable of being used to monitor chronic tox-
icity due to repeat dosing with different timing of toxicity
induction. The inclusion of this tissue model in drug testing
prior to the initiation of phase I clinical trials would allow for
better prediction of the nephrotoxic effects of new drugs [39].
An alternative approach consisted in maintaining the struc-
tural organization of proximal tubules collected from mice by
encapsulating them in commercial HA derived hydrogels
[83]. Despite some oxygen diffusion problems, this model
was able to maintain appropriate biomarker expressions and
some biological functions up to 2 months, thus demonstrating
the potential of the technique for long term drug toxicity as-
says. The preservation of native structural organization and
cell communication appear to be an alternative to better mimic
in vivo organ functions, however, its access is limited by do-
nor availability of tissues, in case it is intended to be used with
human tissues. Recently, a rudimental kidney was developed
and was able to produce urine when transplanted in rat. This
was achieved by seeding decellularized rat kidney scaffolds
(maintaining tissue organization and structures) with kidney
epithelial and endothelial cells, grown in a whole-organ bio-
reactor [84]. Though incipient, this novel technique appears to
be promising to mimic kidney function and therefore its re-
sponse to anti-cancer drugs, both in terms of therapeutic effi-
cacy and nephrotoxicity.
Perhaps the greatest advantage in developing a kidney-like
organoid able to display physiologically relevant functions,
for use in anti-cancer drug development lies precisely in a
better prediction of toxicity, since nephrotoxicity is strong
limiting factor in drug discovery processes, namely in cancer
[82, 83].
Breast Cancer
Breast cancer occurs in tissues of the breast and is the number
one malignant tumor affecting women, although it may also
affect men [3]. Breast cancer is responsible for 23% of female
cancer cases worldwide and is also the leading cause of cancer
deaths, accounting for 14% of total cancer deaths [68].
The interaction of cellular microenvironment and tumor
development is particularly evident in breast cancer, as it has
become clear that perturbations in the cell-ECM interaction
are a distinguishing feature in development of such tumors
[85]. Nevertheless, most drugs currently used to target this
disease have been initially tested using 2D cell cultures.
Particular attention should be placed in choosing the mate-
rial for growing 3D breast cancer cells, since this aspect alone
is able to influence tissue organization [27]. Culturing normal
mammary cells in collagen substrate has resulted in develop-
ment of basement membrane and milk protein production [86,
87]. Their growth in a laminin-rich reconstituted basement
membrane recapitulates in vivo organization of mammary ac-
inus lumen and cells display inverted [88]. A distinctive prop-
erty of malignant cells is precisely the incapacity of forming
such organized structures [89]. Nevertheless, due to its bio-
compatibility and potential to suffer enzymatic degradation,
collagen I hydrogel scaffolds have been proposed as an alter-
native to the creation of 3D in vitro tumors to study pre-
vascularization phases [90]. Maintenance of tissue organiza-
tion, cell proliferation and invasion was achieved by culturing
primary breast cancer cells obtained by biopsy collection in a
collagen I 3D structure [40]. This innovative technique
consisted in making the hydrogels in 24-well plates and leave
it for gelling at 37 °C. Tumor samples are placed on to the
gelling collagen and pushed in to the center using a pipette tip.
The gel is then released using a pipette tip, making it a small
round shape ex vivo 3D model. This ex vivo culture method
has allowed the determination of tamoxifen efficacy in a more
realistic environment, taking into account cellular interactions
between themselves and the surrounding stroma, as this is
believed to be responsible for de novo drug resistance [40].
In this study, tamoxifen reduced residual epithelial volume in
Estrogen receptor positive (ER+) tumors but not in Estrogen
receptor negative ER low/−tumors, as expected. A higher re-
sistance to tamoxifen treatment was also observed for MCF-7
breast cancer cell lines grown on a 3D chitosan scaffold [41],
emphasizing the possibility of 3D cancer models being better
at mimicking tissue responses to drug treatments.
The complex mechanisms underlying 3D cellular re-
sponses to drug treatments has also been pursuit. By adapting
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the reconstituted Basement Membrane culture protocol to
grow MCF10 premalignant progression series of cells, Li
and colleagues [91] managed to develop an in vitro 3D model
of breast cancer progression, from normal breast epithelia to
carcinomous phenotype [91]. This simple model demonstrat-
ed that cells grown in 3D were more resistant to the doxoru-
bicin than in 2D cultures, thought this is more evident in
normal and hyperplastic cells than carcinoma models [44].
However, the response to specific inhibitors was more vari-
able: the exposure to MEK inhibitors, which typically leads to
growth inhibition of MCF10 in 2D, encountered more resis-
tance in both normal and hyperplastic models, while carcino-
ma models demonstrate higher sensitivity towards it. This
higher sensitivity to MEK inhibitors (U0126 and PD184352)
was also registered in MDA-MB-231 basal-subtype breast
carcinoma cells when grown in 3D than 2D. In contrast, inhi-
bition of phosphatidylinositol 3-kinase activity (wortmannin)
had no effect either in 3D or 2D [44].
One of the reasons responsible for deaths associated to
breast cancer is the resistance to chemotherapies and disease
relapses, and breast cancer tumor recurrence has recently been
attributed to a small population of cells, of stem-like charac-
teristics, able to self-renew and to promote tumor progression
[92–94]. These cells, derived from MCF7 cancer cell line,
were successfully isolated using a dye-exclusion method and
were further grown as spheroids, allowing to obtain a 3D
spheroid tumor model with stem-like properties [43]. It was
the first time that the combination of these two methods was
used to select cancer stem cells. Spheroid culture was used
after FACS sorting and plated in ultralow attachment plates.
Subsequently, cells were observed under suspension culture
conditions to detect the stem cell phenotype of tumorsphere
formation [43]. Using this methodology, the authors were able
to screen 1258 compounds of the LOPAC chemical library,
and to unravel the potential to inhibit spheroid formation of
niclosamide (a clinically approved drug used as an anthelmin-
tic agent) thus, emphasizing the potential of this stem-like
enriched spheroid formation technology in breast cancer drug
discovery [43].
As technology evolves, more complex systems are contin-
uously being developed to address drug interactions not only
with target cells but also their non-target secondary effects. A
new complex double system, developed by Lan et al. [45]
allows the prediction of both drug efficacy and hepatotoxicity.
By growing 3D cultures of liver cells encapsulated in alginate
hydrogels together with a breast cancer cell line, they could
assess the cytotoxicity of some commercially available drugs
along with their efficacy. The test platform allowed to evaluate
drug dose concentrations to predict hepatotoxicity and its ef-
fect on the breast cancer cell line. The CT50 value of four
drugs (acetaminophen, diclofenac, rifampin and quinidine)
derived from the dose-dependent testing correlate well with
the reported in vivo LD50 values [45]. Using such systems
could thus become an alternative to minimize the expensive
costs associated to animal testing, estimated in $3 billion a
year [95], which not always render accurate predictions on
drug efficacy and toxicity. The incorporation of breast cancer
tissue models in anti-cancer drug discovery processes would
undoubtedly add relevant knowledge towards the develop-
ment of more suitable therapies to tackle such a complex
disease.
Prostate Cancer
Prostate cancer is the second most common cancer diagnosed
in men, estimated to impact about 40% of men at the age of 60
and 90% of them at the age of 90 years old [68, 96].
Chambers et al. [58] developed a microwell platform and
surface modification protocol to enable high throughput man-
ufacture of 3D cancer aggregates (by forced aggregation pro-
cess), that perfectly allows testing of drug sensitivity and its
comparison with 2D cultures. When docetaxel was tested,
cells cultured in 3D were more resistant to all doses of doce-
taxel than those cultured in 2D. Evenmore interestingly, when
the microaggregates are dispersed and returned to monolayer,
they exhibit the same dose response to docetaxel as those cells
cultured in monolayer, exacerbating the importance of tumor
microenvironment and interactions [58].
It is now becoming more evident the role of the microen-
vironment in prostate cancer invasion, migration and metasta-
tic behavior, as evidenced by the increase in metastatic poten-
tial and cytogenetic abnormalities when in contact with bone
Ametastatic 3Dmodel recapitulated this process by growing a
free-floating mouse bone sample in a bone organ culture me-
dia containing cancer prostate tumor cell lines, LnCap Clone
FGC cell line and PC3 cells, using a roller tube system under
hypoxia [97]. This system revealed that cancer cells preferred
to colonize and proliferate on the Bendosteal side^ of the bone,
further revealing distinct pathophysiological aspects if grown
with breast or prostate cancer cell lines, thus demonstrating
the amazing potential of 3D tissue engineered cancer models
to study such biological events. Also, within this bone-like
microenvironment, prostate cancer cells displayed morpho-
logical plasticity and altered hormonal and proteolytic re-
sponses that were not seen in traditional cell monolayer cul-
ture [97].
Another promising model to validate drugs was developed
by Evensen et al. [59] that allows the segregation between
compounds that inhibit cancer cell invasion and those that
induce cell death. This model consists of a collagen gel
spheroid-based 3-D invasion HT screening tool in an adapted
96-well plate. Cancer cells were combined with neutralized
native type I collagen, dotted into the center of each well of a
96-well plate, and allowed to solidify, ultimately forming a
cell-collagen dot/hemisphere with a distinct boundary and
shape. Following solidification, the cell-collagen hemispheres
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were embedded within a cover-layer of neutralized type I col-
lagen and allowed to solidify. Media supplemented with the
tested drug is added to each well and the cells are allowed to
invade into the surrounding [59]. This system identified nine
compounds exhibiting high potency and low toxicity were
identified, including DX-52-1, a compound previously report-
ed to inhibit cell migration, a critical determinant of cancer
invasion [59].
HA based hydrogels were also used to compare the effica-
cy of three anti-cancer drugs (camptothecin, docetaxel and
rapamycin) in the treatment of bonemetastatic prostate cancer,
using the LNCaP subline C4-2B, typical of bony metastases
[14]. In comparison with 2D cultures, camptothecin displayed
higher induction of apoptosis in 3D, while for the remaining
treatments no significant differences were observed. However,
a combination of docetaxel and rapamycin was more effica-
cious in inducing apoptosis in the HA derived hydrogel. These
different results may reflect the distinct mechanisms of action
and properties of the three drugs, emphasizing the importance
of a proper microenvironment in anti-cancer drug efficacy
assessments.
In the future, these types of 3D–tissue models may contrib-
ute to study the interaction of tumors with its microenviron-
ment, and the way novel drugs may interfere with them.
Immunotherapies have been suggested to be alternatives to
conventional treatments once they become resistant.
However, despite the initial success of using peripheral blood
lymphocytes to target cancer cells in suspension or in 2D
monolayer, its efficacy decreases dramatically when using
3D models [98]. A 3D platform, made of a porous chitosan-
alginate scaffold, has been used to study the interaction of
prostate cancer cells and human peripheral blood lymphocytes
highlighting its potential for use in long-term analysis and for
the development of efficacious immunotherapies [98].
Despite promising, the use of 3D prostate cancer models for
drug discovery appears still to be in its early steps.
Leukaemia
Leukaemia designates cancers that have their origin in tissues
that form blood, such as the bone marrow, triggering the pro-
duction of abnormal white blood cells and their release into
the blood stream. Depending on the speed with which the
disease develops, it can be classified as chronic (slow devel-
opment) or acute (fast development). However, it can also be
classified depending on the cell types affected, being named
lymphoid, lymphocytic, or lymphoblastic when it targets
lymphoid cells and myeloid, myelogenous, or myelo-
blastic when it targets myeloid cells (NCI n.d.).
Disease prognosis depends on several factors, including
the type of leukaemia [99–102].
It is becoming clearer the important role played by the bone
marrowmicroenvironment both in the development of normal
cells and in hematopoietic malignancies. It is the interaction of
supporting cells (which produce growth factors, extracellular
matrix molecules, cytokines and other ligands) with hemato-
poietic stem cells (HSCs) hematopoietic progenitor cells
(HPCs) that regulates important functions such as cell prolif-
eration, differentiation and migration [103]. It has been dem-
onstrated that the induction of apoptosis by asparaginase
(commonly used to treat pediatric acute lymphoblastic leukae-
mia) is blocked when malignant cells are co-cultured with
stroma cells [104]. Despite this, the existence of tissue
engineered models to mimic this bone marrow microenviron-
ment and its interaction with leukaemia development is far
from being achieved.
Significant differences have been observed between con-
ventional polystyrene culture and a co-culture system in a
hollow fiber bioreactor (HFBR) [105]. Erythroleukaemia
K562 cells displayed higher expansion rate when co-
cultured in this system with supporting HS-5 stroma cells
(3130 fold vs. 43 fold), thus evidencing the importance of
cell-cell interactions for myelo-leukemic proliferation. With
the advantage of achieving high cell densities and 3D cellular
contact, the HFBR system recreates a closer mimicry of the
cell-stroma microenvironment which can provide significant
improvements to in vitro studies of stroma-dependent leuke-
mic and hematopoietic cell functions and to study drug
resistance.
One of the reasons suggested to explain leukaemia relapse
after chemotherapy is the existence of leukaemia cell niches in
the bone marrow [106]. This has been mimicked using poly-
urethane scaffolds coated with human mesenchymal stem
cells from the bone marrow, which were further implanted in
a murine host, where they developed a human bone-marrow
like microenvironment, with vascularization, osteoclasts and
adipocytes [106]. Injection of primary human acute myeloid
leukemia cells revealed that these cells preferred the bone-
marrow like scaffold to grow, rather than the host, up to three
months after injection, although theywere able to invade other
tissues of the host after four months. The existence of more
realistic tissue engineered leukaemia models could help to
clarify these mechanisms and to establish more efficacious
therapies. As a step further to establish 3D models of human
acute myeloid leukaemia, three different sub-types of these
cancer cell lines (K-562, HL60 and Kasumi-6) were grown
on highly porous scaffolds made of distinct materials, namely,
PLGA, PU, PMMA, PDLLA, polycaprolactone and PS [107].
Of these, only PU and PLGA allowed the long-term cellular
growth (over a period of 2 months) [107]. The effect of coat-
ing of these scaffolds with collagen I or fibronectin, proteins
constituting the bone marrow ECM was also assessed.
However, each of the cell lines preferred a specific combina-
tion of scaffold/collagen I/fibronectin concentrations [107].
Thus, for the enumerated reasons, such model could poten-
tially have a great impact not only to understand the biology of
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the disease progression, but also in a drug discovery
perspective.
Lung Cancer
Lung cancer has its origin in lung tissues, typically in the cells
lining air passages, and was responsible for 13% of all cancer
cases and 18% (1.4 million) of all deaths caused by cancer in
2008 worldwide [108]. More recently, Huh et al. [109] devel-
oped a biomimetic microsystem that reconstitutes the critical
functional alveolar-capillary interface of the human lung by
seeding human alveolar epithelial cells and microvascular en-
dothelial cells in the microchannels which then attached to
opposite surfaces of the ECM coated membrane. Although
this particular model was not tested yet for drug responses,
the development of cell-based biochips that reproduce com-
plex physiological and pathological responses could revolu-
tionize toxicology field and development of pharmaceuticals
that rely on animal testing and clinical trials [109].
In 2014, Stratmann et al. [57] established an innovative
three-dimensional (3D) lung carcinoma models on a
decellularized tissue matrix (porcine jejunal fragment) seeded
with HCC827 or in A549 cell lines, providing a complex
microenvironment for cell growth. Results show a significant
decrease in proliferation upon gefitinib treatment in the 3D
model when compared to a classic 2D cell monolayer. Once
again, showing that drug treatment of cells grown in 3D con-
ditions on an extracellular matrix scaffold had stronger and
faster effects than in 2D cultured cells, which supports the
notion that the 3D model is more appropriate for further drug
testing.
Recently, a micro-chip co-culture scheme was developed
allowing testing of several concentrations of anti-
chemotherapeutic drugs, single or in combination, under con-
tinuous supply of fresh medium [56]. This polydimethylsilox-
ane microfluidic device was fabricated by replicate molding
on a master onto a glass wafer and patterned by photolithog-
raphy. It contains four units, each of them containing a con-
centration gradient generator, a reservoir and three parallel cell
culture chambers, where a cell basement membrane extract
mixture could be seeded to provide an adequate 3D environ-
ment. Important differences in cell viability responses to gefi-
tinib, paclitaxel and gemcitabine were observed with tests
performed in the human non-small cell lung cancer cell line
(SPCA-1) grown in conventional monolayer, or grown in 3D
in this microfluidic device, as mono-culture or co-cultured
with lung fibroblast cell lines (HFL1). The most significant
differences were observed for patient’s cultured cells exposed
to the anti-cancer agent gefitinib, when compared to SPCA-1
monoculture, thus emphasizing the drug sensitivity differ-
ences observed frequently in 2D cell lines tests and the actual
tumors [56].
Colorectal Cancer
Colorectal cancer it’s originated either in the colon or in rec-
tum of the large intestine. More than 90% of colorectal malig-
nancies are adenocarcinomas (cancerous tumor that can occur
in several parts of the body, defined as neoplasia of epithelial
tissue that with glandular origin, glandular characteristics, or
both). Screening of altered polyps and lesions is the most
effective way to target this disease, for its early detection re-
sults in 5-years survival rates over 90%, compared to only 6%
when detected at later stages. Treatment may include surgery,
chemotherapy, radiotherapy and, less frequently, biological
treatment [110].
A recent study by Mohanty and his team has demonstrated
the potential of HCT-116 colon carcinoma cells grown as
spheroids with 500 μm of diameter to unravel novel chemo-
therapeutic drugs [48]. Using this model, it was evidenced a
potent apoptotic effect of a new small molecule
(NSC647889). Furthermore, mechanistic insights could be
obtained, since resistance to treatment was observed at the
inner core of the spheroids, suggesting that hypoxia and nu-
trient availability may limit the efficacy of the drug in an
in vivo microenvironment [48].
3D spherical structures, designated as colospheres, have
also been obtained spontaneously from colorectal primary tu-
mor tissue subjected to mechanical dissociation [111]. It has
been shown that this ability was cancer cell specific, because
their non-tumoral cell counterparts failed to do so allowing its
distinction, and was significantly correlated to the original
tumor aggressiveness [111]. Furthermore, a subsequent study
has shown that this colospheres had similar genetic pattern to
its original tissue and were able tometastasize when implanted
in mice [50]. Plus, they displayed responses to the conven-
tional colorectal treatment drugs, 5-fluorouracil and
irinotecan, identical to that of conventional xenografts [50].
In order to create an in vitro model able to recapitulate both
tissue architecture and the interaction of tumor with the sur-
rounding stromal cells, Dolzing et al. [52] went further and
engineered a 3D system consisting of colon tumor cells grown
first as spheroids and then co-cultured either with normal or
cancer-associated fibroblasts, on a 3D collagen I scaffold. It
was shown that the interaction between fibroblasts and cancer
cells was responsible for the differential regulation of genes
involved in important cancer associated processes, such as
ECM invasion and remodeling, inflammation and angiogene-
sis, thus demonstrating the usefulness of such a tissue
engineered model to understand cancer mechanisms [52].
Interestingly, Hirt et al. [49] have recently applied the bio-
reactor technology to screen antitumor compounds in colorec-
tal cancer cells seeded on a 3D collagen I scaffold and com-
pare it to traditional 2D cell cultures. Results show that per-
fused 3D cultures resulted in higher cell proliferation than
static 3D cultures with morphology and phenotypes similar
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to xenografts. Treatment with 5-Fluorouracil (5-FU) induced
apoptosis, down-regulation of anti-apoptotic genes (BCL-2,
TRAF1, and c-FLIP) and decreased cell numbers in 2D, but
not in perfused cultures. Conversely, BCL-2 inhibitor ABT-
199 induced cytotoxic effects in 3D perfused cultures but not
in 2D cultures. These findings reveal the importance of perfu-
sion flow in 3D cultures of tumor cells to efficiently mimic
functional features observed in vivo and to test anticancer
compounds [49]. Following the same trend, Chen et al. ((51)
developed a microfluidic platform tomimicking physiological
microenvironment of solid tumor with multicellular tumor
spheroids (MTS) for anticancer drug screening. The
microfluidic device was fabricated from PDMS using soft
lithography and rapid phototyping and has the advantage of
being adapted to a microplate reader and capable to determine
the cytotoxicity of the multicellular tumor spheroids. It con-
stitutes a valuable asset for preclinical screening and
evaluation procedure for anticancer agents with a wide
range of tumors. The spheroids exhibited more resis-
tance to the drugs than those of 2D culture based on
gene expression analysis.
Kim et al. developed a 3D culture system using an
electrospun poly(ε-caprolactone) (PCL) nanofibrous scaffold
(NFS) [53] to study the immune-oncologic interactions as test
the effect of mitoxantrone. Results show that when BM-DCs
(bone marrow derived dendritic cells) were cocultured with
mitoxantrone-treated CT26 cells (colon cancer cells) in a 3D
hybrid NFS, BM-DCs sprouted cytoplasm to, migrated to,
synapsed with, and engulfed mitoxantrone-treated CT26 can-
cer cells, which were similar to the naturally occurring cross-
talk between these two types of cells. The same effect was not
observed in 2D [53]. Such advanced models will represent
new tools for cancer immunobiology studies and for pre-
clinical assessment of innovative treatments.
Much work is still to be done until a 3D colorectal cancer
model that fully mimics its main features can be used in drug
discovery testing. Nevertheless, such model could be a funda-
mental tool, not only to address drug efficacy but also to
increase our understanding of disease progression, from pre-
malignant polyps and lesions to aggressive cancers.
CNS Cancer
CNS cancers are as complex and diversified as the system
they affect, and therefore numerous cancer types have been
defined, according to the cellular lineage in which they are
originated: gliomas (it arises from glial cells, starts in the brain
or spine.), medulloblastomas (the most common type of pedi-
atric malignant primary brain tumor), meningiomas (tumors
arising from the meninges, the membranous layers surround-
ing the central nervous system), lymphomas (lymphoma is a
group of blood cell tumors that develop from lymphatic cells),
pineal tumors (pineal gland tumor), acoustic neuromas
(benign and usually slow-growing tumor that develops on
the main nerve leading from the inner ear to the brain),
haemangioblastoma (tumors of the central nervous system
that originate from the vascular system usually during
middle-age) and pituitary tumors (tumor in the pituitary gland)
[112]. Some of them can also affect the spinal cord, in addition
to the brain. Brain has specific features that make the invasion
process of its tumors quite singular, such as the absence of
collagen, fibronectin and laminin barriers, and its ECM is
mainly composed of hyaluronan, functionalized with proteo-
glycan, critical for cell attachment [113, 114].
Given the described complexity, the impossibility of surgi-
cal removal in many cases and the degree of fatality associated
with these types of cancer, it is clear the need of more efficient
drugs to tackle it. Despite the potential of 3D tissue models as
a study platform to address this need, so far few studies have
been developed in this context, especially given the evidences
of an association between tumor aggressiveness and interac-
tion with ECM, at least in the case of glioblastoma [115].
Spheroid aggregates originated from U-87MG and MO59J
cell lines and from glioblastoma primary culture tissue have
been used to assess the efficacy of radiation therapy and have
allowed the identification of some molecular pathways in-
volved in radioresistance [116].
Other models have attempted to mimic brain ECM and its
involvement in glioblastoma aggressiveness and invasion po-
tential by using HA-based scaffolds [117, 118]. Aspects relat-
ed to the role of stiffness HA hydrogels functionalized with
RGD peptides in the process of gliobastoma invasion have
also been addressed were studied in detail by [115].
Spheroids made of a panel of human and rat glioma cell lines
were allowed to grow in different stiffness HA-hydrogels and
its invasion across it assessed, showing that despite their com-
mon ability to invade the matrix, there were clear differences
in invasion patterns across cell lines. As for denser hydrogels,
they completely blocked spheroid invasion, though allowing
spheroid growth. This model has also showed differences in
cell motility pattern, when compared to both 2D and fibrous
3D collagen-based matrices, and a remarkable resemblance to
that of glioma cells and neural progenitors migrating in brain
slice cultures. Such model could, in the future be used to study
invasion processes and their responsiveness to chemothera-
peutic agents [115]. Additionally, brain tissue engineered
models could be extremely helpful to understand the low ef-
ficacy of glioma treatments, since one of the reasons pointed
to explain it is the existence of blood-brain and glioma-brain
barriers that limit chemicals penetration in target tissues [55].
To address this issue, C6 glioma tumor cell line spheroids
were grown alone or in combination with a monolayer of C6
or b.End 3 cell lines (conventionally used for the replacement
of endothelial cells) to simulate penetration and efficacy of a
novel drug delivery methods to target gliomas, revealing dif-
ferences whether or not the additional cell barrier was present,
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thus emphasizing the need to more complex models to mimic
real conditions when studying anti-cancer drugs [55]
Conclusions
Notwithstanding the historical importance of the NCI-60 cell
line panel in the process of discovering novel cancer therapeu-
tics, it is becoming ever clearer its poor efficacy at predicting
animal and pre-clinical trial outcomes. This happens for rea-
sons associated with physiological differences between natu-
ral environment and 2D cell-culture conditions. Even though,
failure of predictive models happens in other clinical condi-
tions. In the case of cancer studies this is perhaps even more
striking, for it displays complex interactions with the sur-
rounding milieu. They depend on external signals, such as
connections with other cells, with ECM composition and
chemical gradients (such as, oxygen or pH. In contrast, mono-
layer 2D cancer cell cultures are grown in artificial plastic
surfaces, rendering inappropriate topographical stimuli that
culminate in different genetic patterns. Furthermore, drugs
are more easily uptaken and therefore may lead to artificially
higher drug efficacy rates than can never be mimicked in real
conditions, with many more accessibility constraints.
Monolayer cultures are usually exposed to higher levels of
oxygen (typically 21%) while oxygen tumor levels range be-
tween 1 and 5% only, being slightly more elevated in healthy
tissues. 3D models for testing anti-cancer drugs could help
solving some technical difficulties currently faced by common
procedures, such as the poor adhesion properties of cells to
their substrate or the difficulty to maintain their biological
in vivo function. However such progress in research also
brings with new challenges. 3D culture methods represent
and expensive approach and still require solid expertise in
handling and optimization to build good in vitro models, es-
pecially for less trained researchers. In addition, utilizing 3D
cultures with standard cell analysis methods, which were orig-
inally developed to support 2D cultures, can be challenging.
There is a need to develop microfluidic devices to achieve
high detection efficiency that could make use of the multiple
biochemical and physical cues that are distinctive in cancer
[26].
Perhaps the gold standard in drug discovery is the use of
in vivo animal testing, especially in rodents. However, they
present some known limitations, such as differences in im-
mune systems and genetic toolkit, which can explain the re-
duced predictability in some cases. Adding another dimension
to cancer studies would neither replace existing 2D cell cul-
tures nor animal testing, but it could definitively contribute to
improve the predictability of efficacy and toxicity assess-
ments, since 3D models usually display genetic expression
and drug responses behaviors more similar to the actual tu-
mors than their 2D cultures.
Tissue engineering can be the key for the development of
more realistic 3D cancer models. By combining different ex-
tracellular matrix biomaterials with different cell types
(including co-cultures) and different growth factors, it will
be possible to mimic more realistically the complex structural
organization of in vivo tumors. Ultimately, this will allow a
better understanding of the role of particular set of proteins
and/or cell interactions in tumor invasion behavior and hope-
fully enable a more efficient design of anti-cancer drugs and
treatments.
It is clear that much of the success in anti-cancer drug
discovery depends on using representative models, but even
though many studies have demonstrated differences in drug
sensitivity between 2D and 3D models, a demonstration of a
better prediction of clinical outcomes is still missing. Yet,
considering the multitude of potential mechanisms targeted
by anti-cancer therapies, it is more likely that testing per-
formed in 3D heterotypic cultures provides more meaningful
predictions for successful in vivo outcomes than 2D cultures.
The pharmaceutical industry is facing unprecedented chal-
lenges owing to rising costs and the declining efficiency of
drug research and development, mainly due to the poor pre-
dictive capacity of current preclinical models. Pharmaceutical
companies are also beginning to create partnerships with aca-
demic institutions to jointly discover 3D models and organ-
on-a-chip devices technology and to position themselves at
the vanguard of the field. We are also witnessing a growing
number of commercial devices suitable for drug screening,
such as MIMETAS®, Cellix®, 3D BioMatrix®, which can
be applied in cancer research. However, there are many pa-
rameters associated with this kind of research. Between the
choice of polymers, cell types, concentrations and densities,
biomolecules, bioreactors and biochips, regulatory agencies
are understandably cautious in accepting new sources of data
as justification for human trials. Therefore, these models will
have to endure stringent validation to serve as formal preclin-
ical tests.
It is necessary however, that efforts are put into standardi-
zation of such procedures so that the developed 3Dmodel can
be used in routine diagnostic testing, as a bridge to fill in the
gap that currently exists between 2D and animal testing.
Clearly, there is still a long road ahead but there is little doubt
that this is the right direction to pursue in the search for novel
and more efficacious treatments to defeat one of the most
frequent and pernicious diseases of our days, cancer.
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